Verrica Pharmaceuticals
Présence
Verrica Pharmaceuticals fait partie des...
Verrica Pharmaceuticals est une société cotée sous le symbole boursier VRCA (US).
Dirigeants
Voir l'organigramme avec ses 14 principaux dirigeants
Biographies les plus recherchées chez Verrica Pharmaceuticals
- Ted White, Director, President and Chief Executive Officer
- Sean Stalfort, Director
- Lawrence Eichenfield, Director
Créer une alerte
pour suivre les mouvements de dirigeants chez Verrica Pharmaceuticals.
Pharmacie
Verrica Pharmaceuticals a 1 840 concurrents dont Pfizer (Etats—Unis), Johnson & Johnson (Etats—Unis) et Sanofi (France).
Actualités en fusion/acquisition en Pharmacie.
- Kintara Therapeutics and TuHura Biosciences have merged (publié le 10 septembre 2024)..
- Agile Therapeutics and Insud Pharma have announced they will merge (publié le 28 août 2024)..
- Quantum BioPharma changera son nom en Quantum BioPharma le Aug 15, 2024. (publié le 14 août 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP 315 an Investigational Oncolytic Peptide Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma - Verrica Pharmaceutica
- Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP 315 for the Treatment of Basal Cell Carcinoma on August 14 2024 - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories Inc. - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13 2024 - Verrica Pharmaceuticals
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Verrica Pharmaceuticals
- Verrica Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Verrica Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Ted White 
Appelez Verrica Pharmaceuticals au +1 484...
